Boehringer says 味方する 影響s of its obesity 麻薬 were 一貫した with 競争相手s
FRANKFURT, May 10 (Reuters) - The 味方する 影響s of an 実験の obesity 麻薬 that was 実験（する）d in 段階 II by Zealand Pharma and partner Boehringer Ingelheim were 一貫した with those of 類似の GLP-1 based injectable 麻薬s, a Boehringer (n)役員／(a)執行力のある told Reuters.
Paola Casarosa, 長，率いる of 治療力のある areas at Boehringer Ingelheim, also told Reuters that a larger follow-up 裁判，公判 in the third and last 段階 of 麻薬 実験（する）ing was 存在 用意が出来ている and that the two partners were discussing the 裁判，公判 design with 重要な regulators across the world.
GLP-1 based injectable 麻薬s 含む Novo Nordisk´s Wegovy and Ozempic 同様に as Eli Lilly's Mounjaro.
(報告（する）／憶測ing by Ludwig Burger, Editing by Louise Heavens)
